Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide

International Journal of Medical Microbiology

Volumn 301, Issue 1, 2011, Pages 16-25

  Menéndez, Tamara ^a   Santiago Vispo, Nelson F ^a   Cruz Leal, Yoelys ^a   Coizeau, Edelgis ^a   Garay, Hilda ^a   Reyes, Osvaldo ^a   Batista, Yaima ^a   Cobas, Karem ^a   Carmenate, Tania ^a   Chinea, Glay ^a   Guillén, Gerardo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Capsular polysaccharides; Meningococcal vaccines; Neisseria meningitidis; Polysaccharide mimetics

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE LIBRARY; PEPTIDOMIMETIC AGENT; POLYSACCHARIDE; POLYSIALIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIOPHAGE; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; NONHUMAN;

ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS; PEPTIDE LIBRARY; PEPTIDES; POLYSACCHARIDES, BACTERIAL; RATS; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 78649635810     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.04.020     Document Type: Article

References (59)

1. Atherton E., Fox H., Harkiss D., Logan C.J., Sheppard R.C., Williams B.J. A mild procedure for solid phase peptide synthesis: use of fluorenylmethoxycarbonylamino-acids. J. Chem. Soc. Commun. 1978, 537-539.
2. Bhattacharjee A.K., Jennings H.J., Kenny C.P., Martin A., Smith I.C. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem. 1975, 250:1926-1932.
3. Bruge J., Bouveret-Le C.N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22:1087-1096.
4. Carlone G.M., Frasch C.E., Siber G.R., Quataert S., Gheesling L.L., Turner S.H., Plikaytis B.D., Helsel L.O., DeWitt W.E., Bibb W.F. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1992, 30:154-159.
5. Cesareni G., Castagnoli L., Dente L., Iannolo G., Vetriani C., Felici F., Luzzago A., Monaci P., Nicosia A., Cortese R. Construction and utilization of peptide libraries displayed by filamentous bacteriophage. Immunological Recognition of Peptides in Medicine and Biology 1995, CRC Press, Boca Raton, FL, pp. 43-59.
6. de la Cruz V., Lal A.A., McCutchan T.F. Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 1988, 263:4318-4322.
7. Delgado M., Yero D., Niebla O., Gonzalez S., Climent Y., Perez Y., Cobas K., Caballero E., Garcia D., Pajon R. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 2007, 25:8420-8431.
8. Elias J., Harmsen D., Claus H., Hellenbrand W., Frosch M., Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg. Infect. Dis. 2006, 12:1689-1695.
9. Felici F., Castagnoli L., Musacchio A., Jappelli R., Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 1991, 222:301-310.
10. Felici F., Luzzago A., Monaci P., Nicosia A., Sollazzo M., Traboni C. Peptide and protein display on the surface of filamentous bacteriophage. Biotechnol. Annu. Rev. 1995, 1:149-183.
11. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
12. Frank R., Overwin H. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Epitope Mapping Protocols 1996, Humana Press Inc., Totowa, NJ, pp. 149-169.
13. Galfre G., Monaci P., Nicosia A., Luzzago A., Felici F., Cortese R. Immunization with phage-displayed mimotopes. Methods Enzymol. 1996, 267:109-115.
14. Giuliani M.M., du-Bobie J., Comanducci M., Arico B., Savino S., Santini L., Brunelli B., Bambini S., Biolchi A., Capecchi B., Cartocci E., Ciucchi L., Di M.F., Ferlicca F., Galli B., Luzzi E., Masignani V., Serruto D., Veggi D., Contorni M., Morandi M., Bartalesi A., Cinotti V., Mannucci D., Titta F., Ovidi E., Welsch J.A., Granoff D., Rappuoli R., Pizza M. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10834-10839.
15. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969, 129:1307-1326.
16. Granoff D.M., Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., Guarnieri V., Seid R.C., Shan A., Usinger W.R., Tan S., McHugh Y.E., Moe G.R. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 1998, 160:5028-5036.
17. Hankins W.A., Gwaltney J.M., Hendley J.O., Farquhar J.D., Samuelson J.S. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc. Soc. Exp. Biol. Med. 1982, 169:54-57.
18. Hoess R., Brinkmann U., Handel T., Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993, 128:43-49.
19. Hoffman S., Sorkin B.C., White P.C., Brackenbury R., Mailhammer R., Rutishauser U., Cunningham B.A., Edelman G.M. Chemical characterization of a neural cell adhesion molecule purified from embryonic brain membranes. J. Biol. Chem. 1982, 257:7720-7729.
20. Howitz M., Krause T.G., Simonsen J.B., Hoffmann S., Frisch M., Nielsen N.M., Robbins J., Schneerson R., Molbak K., Miller M.A. Lack of association between group B meningococcal disease and autoimmune disease. Clin. Infect. Dis. 2007, 45:1327-1334.
21. Jarvis G.A. Recognition and control of neisserial infection by antibody and complement. Trends Microbiol. 1995, 3:198-201.
22. Jennings H.J., Bhattacharjee A.K., Bundle D.R., Kenny C.P., Martin A., Smith I.C. Structures of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy. J. Infect. Dis. 1977, 136 Suppl.:S78-S83.
23. Jennings H.J., Gamian A., Ashton F.E. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 1987, 165:1207-1211.
24. Jennings H.J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 1981, 127:1011-1018.
25. Jennings H.J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 1986, 137:1708-1713.
26. Kahler C.M., Martin L.E., Shih G.C., Rahman M.M., Carlson R.W., Stephens D.S. The (alpha2→8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect. Immun. 1998, 66:5939-5947.
27. Keyserling H.L., Pollard A.J., DeTora L.M., Gilmet G.P. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev. Vaccines 2006, 5:445-459.
28. Lo Passo C., Romeo A., Pernice I., Donato P., Midiri A., Mancuso G., Arigo M., Biondo C., Galbo R., Papasergi S., Felici F., Teti G., Beninati C. Peptide mimics of the group B meningococcal capsule induce bactericidal and protective antibodies after immunization. J. Immunol. 2007, 178:4417-4423.
29. Mandrell R.E., Azmi F.H., Granoff D.M. Complement-mediated bactericidal activity of human antibodies to poly alpha 2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 1995, 172:1279-1289.
30. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., Arhin F.F., Devi S.J., Frasch C.E., Huang J.C., Kriz-Kuzemenska P., Lemmon R.D., Lorange M., Peeters C.C., Quataert S., Tai J.Y., Carlone G.M. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab Immunol. 1997, 4:156-167.
31. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., Tan C., Mack M., Dasilva I., Alexander K., Mason K., Jiang H.Q., Zhu D., Mininni T.L., Zlotnick G.W., Hoiseth S.K., Jones T.R., Pride M.W., Jansen K.U., Anderson A.S. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27:3417-3421.
32. Menendez, T., De, H.I., Delgado, M., Garay, H., Martin, A., Vispo, N.S., 2001. Immunisation with phage-displayed variable region 2 from meningococcal PorA outer membrane protein induces bactericidal antibodies against Neisseria meningitidis. Immunol. Lett. 78, 143-148.
33. Meola A., Delmastro P., Monaci P., Luzzago A., Nicosia A., Felici F., Cortese R., Galfre G. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J. Immunol. 1995, 154:3162-3172.
34. Moe G.R., Tan S., Granoff D.M. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 1999, 26:209-226.
35. Nakata D., Troy F.A. Degree of polymerization (DP) of polysialic acid (polySia) on neural cell adhesion molecules (N-CAMS): development and application of a new strategy to accurately determine the DP of polySia chains on N-CAMS. J. Biol. Chem. 2005, 280:38305-38316.
36. Nazabal C., Carmenate T., Cruz S., Gonzalez S., Silva R., Musacchio A., Delgado M., Chinea G. Mapping of monoclonal antibodies specific to P64k: a common antigen of several isolates of Neisseria meningitidis. Can. J. Microbiol. 2001, 47:158-164.
37. Park I., Choi I.H., Kim S.J., Shin J.S. Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide. Yonsei Med. J. 2004, 45:755-758.
38. Parmley S.F., Smith G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988, 73:305-318.
39. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 1991, 59:3504-3510.
40. Perrett K.P., Pollard A.J. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert. Opin. Biol. Ther. 2005, 5:1611-1625.
41. Phalipon A., Folgori A., Arondel J., Sgaramella G., Fortugno P., Cortese R., Sansonetti P.J., Felici F. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol. 1997, 27:2620-2625.
42. Pincus S.H., Smith M.J., Jennings H.J., Burritt J.B., Glee P.M. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. J. Immunol. 1998, 160:293-298.
43. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J. 2004, 23:S274-S279.
44. Pon R.A., Lussier M., Yang Q.L., Jennings H.J. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J. Exp. Med. 1997, 185:1929-1938.
45. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning, a Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA. 2nd edn.
46. Saukkonen K., Haltia M., Frosch M., Bitter-Suerman D., Leinonen M. Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. Microb. Pathog. 1986, 1:101-105.
47. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 1989, 7:325-328.
48. Shin J.S., Lin J.S., Anderson P.W., Insel R.A., Nahm M.H. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infect. Immun. 2001, 69:3335-3342.
49. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., Casanueva G.V., Rico C.O., Rodriguez C.R., Terry M.H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991, 14:195-207.
50. Smith G.P., Scott J.K. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993, 217:228-257.
51. Stein D.M., Robbins J., Miller M.A., Lin F.Y., Schneerson R. Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology?. Vaccine 2006, 24:221-228.
52. Tam, J.P., 1995. Synthesis and applications of branched peptides in immunological methods and vaccines. In: Peptides: Synthesis, Structures and Applications. Academic Press, San Diego, CA, pp. 455-500.
53. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
54. Toropainen M., Saarinen L., van der L.P., Kuipers B., Kayhty H. Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model. Microb. Pathog. 2001, 30:139-148.
55. Valadon P., Nussbaum G., Boyd L.F., Margulies D.H., Scharff M.D. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 1996, 261:11-22.
56. Vermont C., van den D.G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol. Med Microbiol. 2002, 34:89-96.
57. Yero D., Pajon R., Perez Y., Farinas M., Cobas K., Diaz D., Solis R.L., Acosta A., Brookes C., Taylor S., Gorringe A. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine 2007, 25:5175-5188.
58. Zollinger W.D., Boslego J.E., Frasch C.E., Froholm L.O. Safety of vaccines containing meningococcal group B polysaccharide. Lancet 1984, 2:166.
59. Zollinger W.D., Moran E.E., Devi S.J., Frasch C.E. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 1997, 65:1053-1060.